|
1
|
Chen YP, Chan ATC, Le QT, Blanchard P, Sun
Y and Ma J: Nasopharyngeal carcinoma. Lancet. 394:64–80.
2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Carioli G, Negri E, Kawakita D, Garavello
W, La Vecchia C and Malvezzi M: Global trends in nasopharyngeal
cancer mortality since 1970 and predictions for 2020: Focus on
low-risk areas. Int J Cancer. 140:2256–2264. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Xiao WW, Huang SM, Han F, Wu SX, Lu LX,
Lin CG, Deng XW, Lu TX, Cui NJ and Zhao C: Local control, survival,
and late toxicities of locally advanced nasopharyngeal carcinoma
treated by simultaneous modulated accelerated radiotherapy combined
with cisplatin concurrent chemotherapy: Long-term results of a
phase 2 study. Cancer. 117:1874–1883. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhang L, Huang Y, Hong S, Yang Y, Yu G,
Jia J, Peng P, Wu X, Lin Q, Xi X, et al: Gemcitabine plus cisplatin
versus fluorouracil plus cisplatin in recurrent or metastatic
nasopharyngeal carcinoma: A multicentre, randomised, open-label,
phase 3 trial. Lancet. 388:1883–1892. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ciardiello F and Tortora G: A novel
approach in the treatment of cancer: Targeting the epidermal growth
factor receptor. Clin Cancer Res. 7:2958–2970. 2001.PubMed/NCBI
|
|
6
|
Lo KW, To KF and Huang DP: Focus on
nasopharyngeal carcinoma. Cancer Cell. 5:423–428. 2004.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW,
Millward MJ, Hong RL, Whang-Peng J, Ma BB, To KF, et al:
Multicenter, phase II study of cetuximab in combination with
carboplatin in patients with recurrent or metastatic nasopharyngeal
carcinoma. J Clin Oncol. 23:3568–3576. 2005.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ueda Y, Enokida T, Okano S, Fujisawa T,
Ito K and Tahara M: Combination treatment with paclitaxel,
carboplatin, and cetuximab (PCE) as first-line treatment in
patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Front Oncol. 10(571304)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Chen C, Zhang X, Zhou Y, Fu S, Lin Z, Hong
S and Zhang L: Treatment of recurrent or metastatic nasopharyngeal
carcinoma by targeting the epidermal growth factor receptor
combined with gemcitabine plus platinum. Cancer Manag Res.
12:10353–10360. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Xu T, Ou X, Shen C and Hu C: Cetuximab in
combination with chemoradiotherapy in the treatment of recurrent
and/or metastatic nasopharyngeal carcinoma. Anticancer Drugs.
27:66–70. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sun XS, Liang YJ, Li XY, Liu SL, Chen QY,
Tang LQ and Mai HQ: Palliative chemotherapy with or without
anti-EGFR therapy for de novo metastatic nasopharyngeal carcinoma:
A propensity score-matching study. Drug Des Devel Ther.
13:3207–3216. 2019.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhao C, Miao J, Shen G, Li J, Shi M, Zhang
N, Hu G, Chen X, Hu X, Wu S, et al: Anti-epidermal growth factor
receptor (EGFR) monoclonal antibody combined with cisplatin and
5-fluorouracil in patients with metastatic nasopharyngeal carcinoma
after radical radiotherapy: A multicentre, open-label, phase II
clinical trial. Ann Oncol. 30:637–643. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhu Y, Yang S, Zhou S, Yang J, Qin Y, Gui
L, Shi Y and He X: Nimotuzumab plus platinum-based chemotherapy
versus platinum-based chemotherapy alone in patients with recurrent
or metastatic nasopharyngeal carcinoma. Ther Adv Med Oncol.
12(1758835920953738)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zong JF, Liang QD, Lu QJ, Liu YH, Xu HC,
Chen BJ, Guo QJ, Xu Y, Hu CR, Pan JJ and Lin SJ: Comparison of
radiotherapy combined with nimotuzumab vs. chemoradiotherapy for
locally recurrent nasopharyngeal carcinoma. BMC Cancer.
21(1274)2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chen C, Zhou Y, Zhang X, Fu S, Lin Z, Fang
W, Yang Y, Huang Y, Zhao H, Hong S and Zhang L: Anti-epidermal
growth factor receptor monoclonal antibody plus palliative
chemotherapy as a first-line treatment for recurrent or metastatic
nasopharyngeal carcinoma. Cancer Med. 9:1721–1732. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chua DT, Wei WI, Wong MP, Sham JS,
Nicholls J and Au GK: Phase II study of gefitinib for the treatment
of recurrent and metastatic nasopharyngeal carcinoma. Head Neck.
30:863–867. 2008.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ma B, Hui EP, King A, To KF, Mo F, Leung
SF, Kam M, Lo YM, Zee B, Mok T, et al: A phase II study of patients
with metastatic or locoregionally recurrent nasopharyngeal
carcinoma and evaluation of plasma Epstein-Barr virus DNA as a
biomarker of efficacy. Cancer Chemother Pharmacol. 62:59–64.
2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
You B, Le Tourneau C, Chen EX, Wang L,
Jarvi A, Bharadwaj RR, Kamel-Reid S, Perez-Ordonez B, Mann V and
Siu LL: A Phase II trial of erlotinib as maintenance treatment
after gemcitabine plus platinum-based chemotherapy in patients with
recurrent and/or metastatic nasopharyngeal carcinoma. Am J Clin
Oncol. 35:255–260. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lee SC, Lim SG, Soo R, Hsieh WS, Guo JY,
Putti T, Tao Q, Soong R and Goh BC: Lack of somatic mutations in
EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal
carcinoma. Pharmacogenet Genomics. 16:73–74. 2006.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500.
2004.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Wakisaka N, Wen QH, Yoshizaki T, Nishimura
T, Furukawa M, Kawahara E and Nakanishi I: Association of vascular
endothelial growth factor expression with angiogenesis and lymph
node metastasis in nasopharyngeal carcinoma. Laryngoscope.
109:810–814. 1999.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Murono S, Inoue H, Tanabe T, Joab I,
Yoshizaki T, Furukawa M and Pagano JS: Induction of
cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is
involved in vascular endothelial growth factor production in
nasopharyngeal carcinoma cells. Proc Natl Acad Sci USA.
98:6905–6910. 2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Elser C, Siu LL, Winquist E, Agulnik M,
Pond GR, Chin SF, Francis P, Cheiken R, Elting J, McNabola A, et
al: Phase II trial of sorafenib in patients with recurrent or
metastatic squamous cell carcinoma of the head and neck or
nasopharyngeal carcinoma. J Clin Oncol. 25:3766–3773.
2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Xue C, Huang Y, Huang PY, Yu QT, Pan JJ,
Liu LZ, Song XQ, Lin SJ, Wu JX, Zhang JW, et al: Phase II study of
sorafenib in combination with cisplatin and 5-fluorouracil to treat
recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol.
24:1055–1061. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Jin Y, Shi YX, Cai XY, Xia XY, Cai YC, Cao
Y, Zhang WD, Hu WH and Jiang WQ: Comparison of five cisplatin-based
regimens frequently used as the first-line protocols in metastatic
nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 138:1717–1725.
2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hui EP, Ma BBY, King AD, Mo F, Chan SL,
Kam MKM, Loong HH, Ahuja AT, Zee BCY and Chan ATC: Hemorrhagic
complications in a phase II study of sunitinib in patients of
nasopharyngeal carcinoma who has previously received high-dose
radiation. Ann Oncol. 22:1280–1287. 2011.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Lim WT, Ng QS, Ivy P, Leong SS, Singh O,
Chowbay B, Gao F, Thng CH, Goh BC, Tan DS, et al: A Phase II study
of pazopanib in Asian patients with recurrent/metastatic
nasopharyngeal carcinoma. Clin Cancer Res. 17:5481–5489.
2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin
ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu
EY, et al: Nonclinical antiangiogenesis and antitumor activities of
axitinib (AG-013736), an oral, potent, and selective inhibitor of
vascular endothelial growth factor receptor tyrosine kinases 1, 2,
3. Clin Cancer Res. 14:7272–7283. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hui EP, Ma BBY, Loong HHF, Mo F, Li L,
King AD, Wang K, Ahuja AT, Chan CML, Hui CWC, et al: Efficacy,
safety, and pharmacokinetics of axitinib in nasopharyngeal
carcinoma: A preclinical and phase II correlative study. Clin
Cancer Res. 24:1030–1037. 2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Zhang Y, Luo F, Ma YX, Liu QW, Yang YP,
Fang WF, Huang Y, Zhou T, Li J, Pan HM, et al: A Phase Ib study of
lucitanib (AL3810) in a cohort of patients with recurrent and
metastatic nasopharyngeal carcinoma. Oncologist. 27:e453–e462.
2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Or YY, Hui AB, To KF, Lam CN and Lo KW:
PIK3CA mutations in nasopharyngeal carcinoma. Int J Cancer.
118:1065–1067. 2006.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Yip WK, Leong VC, Abdullah MA, Yusoff S
and Seow HF: Overexpression of phospho-Akt correlates with
phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal
carcinoma. Oncol Rep. 19:319–328. 2008.PubMed/NCBI
|
|
34
|
Ma BB, Goh BC, Lim WT, Hui EP, Tan EH,
Lopes Gde L, Lo KW, Li L, Loong H, Foster NR, et al: Multicenter
phase II study of the AKT inhibitor MK-2206 in recurrent or
metastatic nasopharyngeal carcinoma from patients in the mayo phase
II consortium and the cancer therapeutics research group (MC1079).
Invest New Drugs. 33:985–991. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Ma BB, Lui VW, Hui CW, Lau CP, Wong CH,
Hui EP, Ng MH, Cheng SH, Tsao SW, Tsang CM, et al: Preclinical
evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal
cancer models. Cancer Lett. 343:24–32. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lu J, Chen XM, Huang HR, Zhao FP, Wang F,
Liu X and Li XP: Detailed analysis of inflammatory cell
infiltration and the prognostic impact on nasopharyngeal carcinoma.
Head Neck. 40:1245–1253. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lee AZE, Tan LSY and Lim CM:
Cellular-based immunotherapy in Epstein-Barr virus induced
nasopharyngeal cancer. Oral Oncol. 84:61–70. 2018.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Brunner MC, Chambers CA, Chan FK, Hanke J,
Winoto A and Allison JP: CTLA-4-Mediated inhibition of early events
of T cell proliferation. J Immunol. 162:5813–5820. 1999.PubMed/NCBI
|
|
39
|
Wherry EJ: T cell exhaustion. Nat Immunol.
12:492–499. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
40
|
Hsu C, Lee SH, Ejadi S, Even C, Cohen RB,
Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, et
al: Safety and antitumor activity of pembrolizumab in patients with
programmed death-ligand 1-Positive nasopharyngeal carcinoma:
Results of the KEYNOTE-028 study. J Clin Oncol. 35:4050–4056.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Stoker SD, Novalić Z, Wildeman MA, Huitema
AD, Verkuijlen SA, Juwana H, Greijer AE, Tan IB, Middeldorp JM and
de Boer JP: Epstein-Barr virus-targeted therapy in nasopharyngeal
carcinoma. J Cancer Res Clin Oncol. 141:1845–1857. 2015.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Fang W, Yang Y, Ma Y, Hong S, Lin L, He X,
Xiong J, Li P, Zhao H, Huang Y, et al: Camrelizumab (SHR-1210)
alone or in combination with gemcitabine plus cisplatin for
nasopharyngeal carcinoma: Results from two single-arm, phase 1
trials. Lancet Oncol. 19:1338–1350. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yang Y, Qu S, Li J, Hu C, Xu M, Li W, Zhou
T, Shen L, Wu H, Lang J, et al: Camrelizumab versus placebo in
combination with gemcitabine and cisplatin as first-line treatment
for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st):
A multicentre, randomised, double-blind, phase 3 trial. Lancet
Oncol. 22:1162–1174. 2021.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW,
Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, et al:
Antitumor activity of nivolumab in recurrent and metastatic
nasopharyngeal carcinoma: An International, multicenter study of
the mayo clinic phase 2 consortium (NCI-9742). J Clin Oncol.
36:1412–1418. 2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Ma Y, Fang W, Zhang Y, Yang Y, Hong S,
Zhao Y, Tendolkar A, Chen L, Xu D, Sheng J, et al: A Phase I/II
open-label study of nivolumab in previously treated advanced or
recurrent nasopharyngeal carcinoma and other solid tumors.
Oncologist. 24:891–e431. 2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Wei XL, Ren C, Wang FH, Zhang Y, Zhao HY,
Zou BY, Wang ZQ, Qiu MZ, Zhang DS, Luo HY, et al: A phase I study
of toripalimab, an anti-PD-1 antibody, in patients with refractory
malignant solid tumors. Cancer Commun (Lond). 40:345–354.
2020.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu
XC, Liao W, Jiang Y, Lin XY, Zhang QY, et al: Efficacy, safety, and
correlative biomarkers of toripalimab in previously treated
recurrent or metastatic nasopharyngeal carcinoma: A phase II
clinical trial (POLARIS-02). J Clin Oncol. 39:704–712.
2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen
J, Li J, Shi YR, Jin F, Xu R, et al: Toripalimab or placebo plus
chemotherapy as first-line treatment in advanced nasopharyngeal
carcinoma: A multicenter randomized phase 3 trial. Nat Med.
27:1536–1543. 2021.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hua Y, You R, Wang Z, Huang P, Lin M,
Ouyang Y, Xie Y, Zou X, Liu Y, Duan C, et al: Toripalimab plus
intensity-modulated radiotherapy for recurrent nasopharyngeal
carcinoma: An open-label single-arm, phase II trial. J Immunother
Cancer. 9(e003290)2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Chia WK, Wang WW, Teo M, Tai WM, Lim WT,
Tan EH, Leong SS, Sun L, Chen JJ, Gottschalk S and Toh HC: A phase
II study evaluating the safety and efficacy of an
adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients
with advanced metastatic nasopharyngeal carcinoma. Ann Oncol.
23:997–1005. 2012.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Smith C, Tsang J, Beagley L, Chua D, Lee
V, Li V, Moss DJ, Coman W, Chan KH, Nicholls J, et al: Effective
treatment of metastatic forms of Epstein-Barr virus-associated
nasopharyngeal carcinoma with a novel adenovirus-based adoptive
immunotherapy. Cancer Res. 72:1116–1125. 2012.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Louis CU, Straathof K, Bollard CM,
Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H,
et al: Adoptive transfer of EBV-specific T cells results in
sustained clinical responses in patients with locoregional
nasopharyngeal carcinoma. J Immunother. 33:983–990. 2010.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Huang J, Fogg M, Wirth LJ, Daley H, Ritz
J, Posner MR, Wang FC and Lorch JH: Epstein-Barr virus-specific
adoptive immunotherapy for recurrent, metastatic nasopharyngeal
carcinoma. Cancer. 123:2642–2650. 2017.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Chia WK, Teo M, Wang WW, Lee B, Ang SF,
Tai WM, Chee CL, Ng J, Kan R, Lim WT, et al: Adoptive T-cell
transfer and chemotherapy in the first-line treatment of metastatic
and/or locally recurrent nasopharyngeal carcinoma. Mol Ther.
22:132–139. 2014.PubMed/NCBI View Article : Google Scholar
|
